Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.42 |
| ▸ | ITK | Q08881 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499131 | 0.93 | LCK (0.44) | LCKJAK3BTKTNK2TTK | |
| SCHEMBL4484530 | 0.92 | LCK (0.43) | LCKJAK3BTKTNK2TTK | |
| SCHEMBL4502146 | 0.91 | LCK (0.47) | LCKJAK3BTKTNK2PDE4A | |
| SCHEMBL5686291 | 0.90 | LCK (0.46) | LCKJAK3BTKTNK2TTK | |
| SCHEMBL4499766 | 0.90 | LCK (0.46) | LCKJAK3BTKTNK2PTK2 | |
| SCHEMBL4494883 | 0.89 | LCK (0.48) | LCKJAK3BTKTNK2 | |
| SCHEMBL4483160 | 0.89 | LCK (0.49) | LCKJAK3BTKTNK2TTK | |
| SCHEMBL4501181 | 0.88 | LCK (0.55) | LCKJAK3BTKTNK2ITK | |
| SCHEMBL4495907 | 0.87 | LCK (0.47) | LCKJAK3BTKTNK2 | |
| SCHEMBL4488109 | 0.85 | LCK (0.47) | LCKJAK3BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | LCK 33/4885JAK3 900/4885BTK 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.